Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.

PubWeight™: 1.25‹?› | Rank: Top 10%

🔗 View Article (PMC 3150219)

Published in J Immunol on July 08, 2011

Authors

Cristina Penaranda1, Qizhi Tang, Jeffrey A Bluestone

Author Affiliations

1: Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.

Articles citing this

Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells. Am J Transplant (2013) 1.52

CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45

Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology (2017) 1.41

Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol (2016) 1.15

Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity (2011) 1.13

Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells. Indian J Med Res (2013) 1.13

Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med (2012) 1.10

Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes (2012) 1.02

Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00

Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology (2014) 0.96

IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95

Immune Regulation in T1D and T2D: Prospective Role of Foxp3+ Treg Cells in Disease Pathogenesis and Treatment. Front Endocrinol (Lausanne) (2013) 0.93

T cells in the control of organ-specific autoimmunity. J Clin Invest (2015) 0.93

Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91

The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J Autoimmun (2015) 0.91

Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease. Clin Exp Immunol (2013) 0.88

Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol (2015) 0.85

Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85

Altered generation of induced regulatory T cells in the FVB.mdr1a-/- mouse model of colitis. Mucosal Immunol (2012) 0.85

Inducing and Administering Tregs to Treat Human Disease. Front Immunol (2016) 0.84

Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment. PLoS One (2013) 0.82

Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med (2016) 0.80

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. Rev Diabet Stud (2012) 0.80

Differential response of regulatory and conventional CD4⁺ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action? J Immunol (2013) 0.80

Eliminating encephalitogenic T cells without undermining protective immunity. J Immunol (2013) 0.79

Prospects for therapeutic tolerance in humans. Curr Opin Rheumatol (2014) 0.78

Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case. Microb Cell Fact (2014) 0.77

Eukaryotic translation initiation factor 5A inhibition alters physiopathology and immune responses in a "humanized" transgenic mouse model of type 1 diabetes. Am J Physiol Endocrinol Metab (2014) 0.77

Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. PLoS One (2013) 0.77

Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them? J Immunol (2016) 0.76

Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth. Diabetes Technol Ther (2013) 0.76

Lacrimal Gland Inflammation Deregulates Extracellular Matrix Remodeling and Alters Molecular Signature of Epithelial Stem/Progenitor Cells. Invest Ophthalmol Vis Sci (2015) 0.76

Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets (2013) 0.76

Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance. Front Immunol (2015) 0.75

Anti-CD3 antibody treatment induces hypoglycemia and super tolerance to glucose challenge in mice through enhancing glucose consumption by activated lymphocytes. J Immunol Res (2014) 0.75

Regulatory T Cells: Central Concepts from Ontogeny to Therapy. Transfus Med Rev (2016) 0.75

Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3Ɛ humanized mice treated with polyclonal anti human thymocyte globulin. PLoS One (2017) 0.75

Exacerbation of spontaneous autoimmune nephritis following regulatory T cell depletion in B cell lymphoma 2-interacting mediator knock-out mice. Clin Exp Immunol (2017) 0.75

Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes. Immunotargets Ther (2017) 0.75

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol (2017) 0.75

Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. Proc Natl Acad Sci U S A (2017) 0.75

Articles cited by this

Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol (2010) 9.72

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 8.63

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest (2003) 6.42

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08

Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ (2002) 4.64

Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity (2002) 4.61

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40

Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev (1998) 3.92

CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol (1997) 2.89

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95

Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 1.67

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation (1989) 1.50

Apoptosis and the homeostatic control of immune responses. Curr Opin Immunol (2007) 1.49

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation (1999) 1.43

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38

An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol (1995) 1.34

Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med (1989) 1.34

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med (1997) 1.33

Overview: apoptotic signaling pathways in the immune system. Immunol Rev (2003) 1.29

Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol (2002) 1.26

Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today (1994) 1.17

Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol (1998) 1.03

Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol (1992) 0.98

Essential roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells. J Leukoc Biol (2007) 0.97

Impaired T cell receptor signaling in Foxp3+ CD4 T cells. Ann N Y Acad Sci (2007) 0.96

OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation (1991) 0.96

CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J Immunol (2003) 0.95

2-Gy whole-body irradiation significantly alters the balance of CD4+ CD25- T effector cells and CD4+ CD25+ Foxp3+ T regulatory cells in mice. Cell Mol Immunol (2010) 0.94

Perturbed homeostasis of peripheral T cells elicits decreased susceptibility to anti-CD3-induced apoptosis in prediabetic nonobese diabetic mice. J Immunol (2004) 0.84

Immunologic monitoring with monoclonal antibodies to human T-cell subsets. Transplant Proc (1981) 0.78

Articles by these authors

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33

Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44

The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94

Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes (2005) 4.19

Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03

Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70

Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40

Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18

A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07

CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04

Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86

IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab (2012) 2.80

NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68

Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54

Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52

Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21

Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13

Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13

How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol (2005) 2.12

CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90

Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes (2013) 1.79

Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74

How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74

Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73

Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A (2004) 1.69

Murine pancreatic islet isolation. J Vis Exp (2007) 1.68

Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67

Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67

A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65

Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63

Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61

Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55

IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54

T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol (2008) 1.52

The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50

Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49

CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45

Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol (2013) 1.42

Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38

Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33

Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29

Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp (2007) 1.28

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28

Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27

The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med (2011) 1.26

Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26

When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol (2002) 1.25

Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice. J Clin Invest (2011) 1.25

Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol (2003) 1.25

CTLA-4 and tolerance: the biochemical point of view. Immunol Res (2003) 1.24

Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol (2013) 1.24

The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol (2002) 1.24

Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23

Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2003) 1.20

Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. J Immunol (2009) 1.18

T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol (2009) 1.16

Inability to induce tolerance through direct antigen presentation. Am J Transplant (2002) 1.16

Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol (2008) 1.14

The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol (2002) 1.13